Subscribe

RSS Feed (xml)

Powered By

Skin Design: Kisi Karunia
Base Code: Free Blogger Skins

Powered by Blogger

Saturday, 21 November 2026

A New Generation of Jembrana Vaccine! Can Nanotechnology Provide More Effective Protection for Bali Cattle?

 


Nanotechnology-Based Development of a Jembrana Disease Virus (JDV) Vaccine: A Novel Approach to Protecting Bali Cattle (Bos javanicus)

 

ABSTRACT

 

Jembrana disease is an acute infectious disease of Bali cattle (Bos javanicus) caused by Jembrana disease virus (JDV), a member of the genus Lentivirus within the family Retroviridae. The disease exhibits unusual clinical characteristics compared with most lentiviral infections in mammals, including high fever, thrombocytopenia, hematological abnormalities, and a significant risk of mortality. Disease control in Indonesia has included the use of inactivated tissue-based vaccines, which have demonstrated benefits in reducing viral load and mitigating the risk of transmission. However, reliance on animal-derived biological materials, the need for production standardization, and limitations in protection against infection highlight the need to develop alternative vaccine platforms. This article aims to review the potential application of nanotechnology in the development of next-generation JDV vaccines, particularly through lipid nanoparticles (LNPs), poly(lactic-co-glycolic acid) (PLGA) nanoparticles, and chitosan-based nanocarriers. Potential vaccine antigens include envelope glycoproteins, particularly the surface unit (Env-SU), as well as nonstructural antigens such as Tat, which require further evaluation in terms of immunogenicity and safety. Nanodelivery systems may protect antigens or nucleic acids, enhance uptake by antigen-presenting cells, and support the induction of both humoral and cellular immune responses. Nevertheless, their ability to enhance cross-presentation through major histocompatibility complex class I (MHC-I), prolong antigen release, and provide superior protection against JDV infection remains to be experimentally demonstrated. Further studies should include physicochemical characterization, formulation stability, safety assessment, immunogenicity evaluation, and challenge-protection studies in Bali cattle, in accordance with applicable ethical and biosafety requirements. Nanotechnology has the potential to provide a foundation for developing JDV vaccines that are more standardized, safer, and suitable for sustainable production.

 

Keywords: Jembrana disease virus, Bali cattle, nanotechnology, subunit vaccine, lipid nanoparticles, PLGA, chitosan.

 

1. INTRODUCTION

 

Jembrana disease is a contagious disease that primarily affects Bali cattle and was first recognized in Jembrana Regency, Bali, Indonesia. The causative agent is Jembrana disease virus (JDV), a positive-sense, single-stranded RNA virus belonging to the family Retroviridae and the genus Lentivirus. Although JDV is genetically related to bovine immunodeficiency virus (BIV), it causes a distinct disease presentation, particularly due to its acute course of infection in Bali cattle (Desport & Lewis, 2010).

 

The clinical manifestations of Jembrana disease include high fever, enlargement of lymph nodes, thrombocytopenia, hematological abnormalities, and, in severe cases, death. Reported mortality rates vary depending on the affected population, outbreak conditions, and characteristics of the infection. Therefore, the mortality rate of approximately 15–20%, which is frequently cited, should be interpreted as a range reported under specific circumstances rather than a universal figure applicable to all disease outbreaks (Desport & Lewis, 2010).

 

Controlling this disease is essential to protecting Bali cattle populations as an important indigenous livestock genetic resource of Indonesia. In addition to causing economic losses, Jembrana disease outbreaks can hinder livestock development, animal trade, and programs aimed at improving the productivity of local cattle breeds.

 

One control strategy that has been implemented is the use of inactivated tissue-based vaccines. Hartaningsih et al. (2001) demonstrated that vaccines produced using virus-containing materials derived from plasma and spleen tissues, followed by inactivation and formulation with an adjuvant, could reduce the duration and severity of the disease. However, vaccination does not completely prevent disease development following viral challenge. Research by Ditcham et al. (2009) also demonstrated that tissue-based vaccination could reduce viral loads above the threshold associated with transmission risk by 96% compared with the control group. These findings demonstrate the benefits of vaccination while highlighting the need for continued improvements in disease control effectiveness.

 

The use of animal-derived biological materials as antigen sources also presents challenges related to raw material consistency, quality control, production capacity, and biological safety testing requirements. These challenges provide a rationale for exploring recombinant subunit vaccines and nucleic acid-based vaccines that do not require antigen production through the harvesting of organs from infected animals.

 

Nanotechnology offers a relevant approach because it can be used to protect antigens, regulate delivery characteristics, and influence interactions between antigens and the immune system. Various nanoparticle platforms have been developed in modern vaccinology, including lipid nanoparticles (LNPs) for mRNA delivery and polymeric nanoparticles for antigen formulation. However, the success of these platforms against other diseases does not automatically establish their effectiveness against JDV.

 

Against this background, this article reviews strategies for developing nanotechnology-based JDV vaccines, with particular emphasis on antigen selection, delivery platforms, immunological mechanisms, product characterization, and the research stages required before their potential application in livestock production systems.

 

2. METHODOLOGY

 

This article was prepared using a narrative literature review approach focusing on Jembrana disease, the characteristics of JDV, inactivated tissue-based vaccines, and advances in nanoparticle-based vaccine delivery systems. The literature reviewed included experimental studies on JDV vaccines, review articles on disease pathogenesis and control, and publications addressing lipid nanoparticles (LNPs) and the stability of mRNA vaccines.

 

The collected information was analyzed using a descriptive-comparative approach based on five main aspects: antigen selection, delivery material characteristics, mechanisms of immune response induction, potential for large-scale production, and safety and stability challenges.

 

As this article constitutes a narrative review rather than an experimental study, no nanoparticle formulation, laboratory testing, or viral challenge experiments were conducted. Therefore, the potential advantages of nanotechnology-based vaccines against JDV discussed in this article are presented as scientifically plausible prospects requiring further validation, rather than as experimentally demonstrated efficacy outcomes.

 

3. RESULTS AND DISCUSSION

 

3.1. Characteristics of JDV and Their Implications for Vaccine Development

 

JDV exhibits interesting biological characteristics because it belongs to the genus Lentivirus yet can cause acute disease in Bali cattle. Upon entering susceptible cells, the virus undergoes reverse transcription, converting its RNA genome into DNA, which can subsequently integrate into the host cell genome as proviral DNA. This process is a defining characteristic of retroviruses and represents an important consideration in vaccine platform selection (Desport & Lewis, 2010).

 

These characteristics have two major implications. First, an ideal vaccine should induce antibodies capable of inhibiting viral infection, as well as cellular immune responses that can help control infected cells. Second, vaccine platforms should avoid the use of replication-competent live viruses unless their safety has been subjected to rigorous evaluation.

 

Inactivated vaccines can provide clinical protection; however, research findings indicate that such protection does not necessarily translate into complete prevention of infection. Therefore, the performance of next-generation JDV vaccines should be evaluated using multiple indicators, including disease severity, duration of fever, viral load, antibody responses, T-cell responses, and the potential for viral transmission.

 

The development of nanotechnology-based vaccines should be guided by these biological requirements rather than solely by the ability to produce particles within the nanometer range. Particle size represents only one formulation parameter, whereas vaccine performance depends on the overall interplay among the antigen, delivery system, immune responses, safety, and protection against disease.

 

3.2. Selection of JDV-Specific Target Antigens

 

Antigen selection is one of the most critical steps in the development of subunit vaccines and nucleic acid-based vaccines. Two potential candidates that warrant consideration are envelope glycoproteins and the regulatory protein Tat.

 

3.2.1. Envelope Surface Unit (Env-SU)

 


The Env-SU protein is part of the envelope glycoprotein complex involved in viral interactions with host cells. Because it is located on the surface of viral particles, this protein represents a relevant target for vaccine development aimed at inducing antibodies that may inhibit viral entry into host cells.

 

In vaccine development, recombinant Env-SU antigen may be considered as a subunit protein delivered using polymeric nanoparticles. Alternatively, mRNA encoding the selected antigen can be delivered through lipid nanoparticles (LNPs), enabling host cells to produce the antigenic protein.

 

However, antigen design must take into account protein structure, glycosylation, conformation, and the preservation of epitopes recognized by antibodies. Recombinant proteins that fail to maintain the appropriate antigenic structure may not necessarily induce effective neutralizing antibodies.

 

Therefore, the suitability of Env-SU as a vaccine candidate should be determined through antigen expression studies, recognition by specific antibodies, evaluation of its ability to induce neutralizing antibodies, and assessment of its correlation with protection against disease. Computational codon optimization may help improve protein expression; however, it does not, by itself, establish vaccine efficacy.


3.2.2. Tat Protein

 


Tat is a regulatory protein involved in the regulation of viral transcription through its interaction with transcriptional regulatory elements. Its role in JDV replication dynamics makes this protein an interesting candidate for investigation as a potential source of epitopes for inducing T-cell responses.

 

Unlike Env-SU, which is located on the viral surface, Tat is not a primary target for neutralizing antibodies against free viral particles. Its potential value is more closely associated with the possibility of inducing cellular immune responses against antigens expressed within infected cells.

 

Nevertheless, the use of Tat as a vaccine component requires specific assessments of its safety, antigenic form, and ability to induce relevant immune responses. Protein-based strategies or genetic constructs must be carefully designed to avoid unintended viral regulatory activity.

 

Therefore, the incorporation of Env-SU and Tat into a single formulation represents a development hypothesis that warrants experimental investigation, rather than a combination that has already been demonstrated to provide optimal protection in Bali cattle.

 

3.3. Nanotechnology Platforms for JDV Vaccines


Two major platform categories warrant consideration: lipid nanoparticles (LNPs) for nucleic acid delivery and biodegradable polymeric nanoparticles for protein antigen delivery.

 

3.3.1. Lipid Nanoparticles for mRNA Vaccines

  


Lipid nanoparticles (LNPs) are delivery systems that have been widely used in the development of mRNA vaccines. Their formulations may include ionizable lipids, helper phospholipids, cholesterol, and polyethylene glycol (PEG)-conjugated lipids.

 

Ionizable lipids facilitate nucleic acid encapsulation and contribute to cargo release from endosomal compartments. Phospholipids and cholesterol support particle structure and physicochemical properties, whereas PEG-lipids can influence particle size, colloidal stability, and interactions with the biological environment.

 

Conceptually, this platform can be investigated for the delivery of mRNA encoding selected JDV antigens. Following administration, the particles may be taken up by cells, including antigen-presenting cells. The mRNA that successfully reaches the cytoplasm is translated into antigenic proteins, which can subsequently be processed and presented to immune cells.

 

Studies on mRNA-LNP vaccines have demonstrated the potential of this platform to induce both humoral and cellular immune responses. However, the stability of mRNA and LNPs is influenced by formulation composition, storage temperature, and distribution conditions. Some mRNA vaccine formulations require frozen or ultra-low-temperature storage, making cold-chain stability an important challenge for implementation in remote livestock farming areas (Schoenmaker et al., 2021).

 

Therefore, the development of LNPs for JDV vaccines should consider not only delivery efficiency but also storage stability, distribution feasibility, cost per dose, and compatibility with Indonesia's veterinary healthcare delivery systems.

 

3.3.2. PLGA Nanoparticles for Subunit Vaccines

  


Poly(lactic-co-glycolic acid) (PLGA) is a biodegradable polymer that has been extensively investigated for drug and antigen delivery applications. This material can form nanoparticle matrices that help protect biological cargo and influence its release characteristics.

 

For JDV vaccines, recombinant antigens such as Env-SU may be considered as payloads for PLGA nanoparticles. Antigen release characteristics are influenced by particle size, polymer composition, antigen properties, and environmental conditions. With appropriate optimization, PLGA has the potential to maintain antigen availability and regulate its interactions with antigen-presenting cells.

 

Nevertheless, sustained antigen release does not automatically replace the function of booster vaccination. Long-lasting immune responses require adequate antigenic stimulation, the development of immunological memory cells, and appropriate regulation of immune responses. Therefore, the claim that a single PLGA-based vaccine dose could replace two conventional vaccination doses must be demonstrated through experimental comparisons with conventional vaccination schedules.

 

Furthermore, PLGA formulations must address potential antigen degradation during manufacturing and storage, encapsulation efficiency, and antigen release profiles. These parameters are essential for maintaining product quality consistency.

 

3.3.3. Chitosan Nanoparticles

  


Chitosan is a polymer derived from chitin that possesses positively charged functional groups under certain conditions. These physicochemical properties enable interactions with negatively charged molecules, making chitosan a potential material for the delivery of both antigens and nucleic acids.

 

Chitosan has potential applications in the formulation of mucosally administered vaccines. Its mucoadhesive properties may help retain formulations on mucosal surfaces; however, delivery performance depends on particle size, surface charge, solubility, mucus characteristics, and the biological conditions at the administration site.

 

For JDV vaccine development, chitosan-based formulations can be investigated as alternatives to parenteral administration. However, intranasal or oral administration cannot be considered more effective solely on the basis of chitosan's mucoadhesive properties. Their effectiveness must be demonstrated through the assessment of mucosal immune responses, tissue safety, systemic immune responses, and protection against disease.

 

Chitosan is also not necessarily stable or optimally soluble under all physiological conditions. Therefore, its composition, raw material characteristics, and final product quality must be standardized before further development for veterinary applications.

 

3.4. Mechanisms of Immune Response Enhancement

 

One of the objectives of developing nanotechnology-based vaccines is to improve antigen uptake by antigen-presenting cells, including dendritic cells. These cells process antigens and present them through major histocompatibility complex (MHC) molecules to T lymphocytes, thereby linking innate immune responses with adaptive immune responses.

 

3.4.1. Antigen Presentation through MHC-I and MHC-II

 



Antigens produced intracellularly, for example following mRNA vaccine administration, can be processed through the major histocompatibility complex class I (MHC-I) presentation pathway for recognition by CD8+ T cells. Activated CD8+ T cells can contribute to the recognition and control of cells expressing the corresponding antigens.

 

Meanwhile, antigens taken up from the extracellular environment are generally processed through the MHC class II (MHC-II) pathway to activate CD4+ T cells. Some extracellular antigens may also enter the MHC-I cross-presentation pathway, depending on antigen properties, the type of antigen-presenting cell, and the characteristics of the delivery system.

 

Nanoparticles can influence these processes through their size, surface charge, composition, and distribution patterns within tissues. However, particle sizes resembling those of viral particles do not, by themselves, guarantee effective antigen cross-presentation.

 

In the context of JDV vaccines, the success of this approach should be evaluated by assessing T-cell activation profiles, cytokine production, antibody responses, and relevant indicators of protection. Even strong cellular immune responses must be interpreted alongside safety data and clinical outcomes.

 

3.4.2. Activation of Innate Immunity

 


The innate immune system recognizes various molecular signals through pattern recognition receptors (PRRs). Activation of specific signaling pathways can promote the production of cytokines and interferons, which help shape the development of adaptive immune responses.

 

Certain components of nucleic acid-based vaccines may influence innate immune recognition; however, the activation of specific pathways cannot be assumed solely because a formulation incorporates nanoparticles. These effects depend on material composition, cargo characteristics, delivery location, and the types of cells exposed to the formulation.

 

Toll-like receptor (TLR) and cyclic GMP-AMP synthase–stimulator of interferon genes (cGAS-STING) pathways are examples of immune recognition systems relevant to vaccinology. However, these pathways involve distinct recognition and activation mechanisms. The cGAS-STING pathway is primarily associated with the recognition of DNA in the cytosol, whereas RNA recognition involves other receptors and mechanisms, depending on the molecular characteristics of the RNA.

 

Therefore, the selection of adjuvants and delivery systems for JDV vaccines should be based on the intended immune response and experimental findings, rather than on the assumption that all nanoparticles activate the same immune signaling pathways.

 

3.5. Comparison of JDV Vaccine Development Strategies

 

The following comparison describes the general characteristics of each platform and does not represent the results of direct comparative trials against JDV (Table 1).

 

Table 1. Comparative Characteristics of Different Vaccine Platforms for Jembrana Disease Virus (JDV) Development

 

Parameter

Inactivated Tissue-Based Vaccine

PLGA/Chitosan-Based Subunit Vaccine

LNP-Based Nucleic Acid Vaccine

Antigen source

Processed animal-derived biological materials from tissues or plasma

Recombinant antigens produced under controlled conditions

mRNA or DNA encoding selected antigens

Biological safety

Requires validated inactivation procedures and control of adventitious agents

Does not require intact virus; antigen quality must still be controlled

Does not require replication-competent JDV

Immune response

Can induce antibody responses and clinical protection

Has the potential to induce humoral responses; cellular responses depend on the formulation

Has the potential to induce both humoral and cellular immune responses

Antigen release

Depends on vaccine formulation and its characteristics

Can be engineered to regulate antigen release

Depends on nucleic acid stability and antigen expression

Stability

Determined by formulation and storage conditions

Depends on the polymer, antigen, and manufacturing process

Depends on nucleic acid design and LNP composition

Scalability

Depends on the availability of biological materials and processing procedures

Potentially scalable through recombinant production and standardized formulation processes

Potentially scalable through nucleic acid synthesis and formulation processes

Major challenges

Raw material consistency, inactivation validation, and quality control

Antigen stability, encapsulation efficiency, and release consistency

Storage stability, cost, and delivery efficiency

Status for JDV

Already implemented, with evidence of beneficial effects

Requires further development and JDV-specific validation

Requires further development and JDV-specific validation

Source: Hartaningsih et al. (2001), Ditcham et al. (2009), Desport and Lewis (2010), and Schoenmaker et al. (2021).

 

This comparison demonstrates that each platform has its own advantages and limitations. Tissue-based vaccines have direct evidence of benefits against Jembrana disease, whereas nanotechnology-based platforms offer opportunities to improve production consistency and modulate immune responses. Therefore, replacing currently used vaccines should be based on evidence demonstrating that new candidates meet, at a minimum, the required standards of safety, quality, and efficacy.

 

3.6. Challenges in Development and Translation to Practical Application

 

3.6.1. Standardization of Physicochemical Characteristics

 

Nanoparticle characterization is an essential component of quality control. Key parameters include particle size, size distribution, polydispersity index (PDI), surface charge or zeta potential, encapsulation efficiency, antigen content, and storage stability.

 

Mean particle size alone is insufficient to describe formulation quality. A broad particle-size distribution may affect product consistency, whereas changes in zeta potential may provide information about colloidal stability under specific testing conditions.

 

Encapsulation efficiency should also be distinguished from the amount of antigen that retains its biological activity. Although an antigen may be successfully incorporated into nanoparticles, structural alterations may occur that reduce its immunological recognition. Therefore, physicochemical characterization should be accompanied by methods for evaluating antigen integrity and biological activity.

 

3.6.2. Stability and the Cold Chain

 

Stability is a critical factor in the practical application of vaccines in Indonesian livestock production systems. Temperature, humidity, light exposure, transportation conditions, and storage duration can all affect product quality.

 

LNP-mRNA vaccines face challenges related to nucleic acid stability and nanoparticle structural integrity. Certain formulations require low-temperature storage, although the development of stabilization and drying methods continues to be investigated (Schoenmaker et al., 2021).

 

Meanwhile, the use of PLGA and chitosan does not automatically guarantee improved stability under tropical conditions. Stability must still be demonstrated through appropriate real-time and accelerated testing, including assessments of vaccine potency after storage and simulated distribution conditions.

 

3.6.3. Production Costs and Scalability

 

Veterinary vaccines must take into account the cost per dose, ease of production, availability of raw materials, and distribution capacity. Recombinant and nucleic acid-based platforms have the potential to reduce dependence on animal-derived biological materials. However, synthesis, purification, formulation, and quality control costs may represent substantial components of overall production costs.

 

Chitosan may be an attractive material for further investigation because of its properties as a natural polymer, whereas PLGA offers flexibility in controlling cargo release. Nevertheless, material selection should not be based solely on raw material prices. Overall processing costs, batch-to-batch consistency, product stability, and the need for booster doses must also be considered.

 

An economic feasibility assessment is therefore essential to determine whether a particular platform can be practically implemented in a nationwide vaccination program for Bali cattle.

 

3.6.4. Safety and Regulatory Requirements

 

The development of nanotechnology-based vaccines requires comprehensive safety assessments, including local tolerability, systemic reactions, potential adverse effects of the delivery materials, and the safety of repeated administration. For nucleic acid-based vaccines, the evaluation should also address antigen expression characteristics and biological risks relevant to the specific product design.

 

Vaccines that do not contain intact JDV particles offer the advantage of reducing dependence on the handling of whole viruses during the manufacturing process. However, this characteristic does not automatically imply that the resulting products are risk-free. The overall safety profile must be established through appropriate testing in accordance with the vaccine type and the requirements of the relevant veterinary regulatory authorities.

 

3.7. Recommended Research and Development Stages

 

The development of nanotechnology-based JDV vaccines should follow a phased approach to ensure that scientific decisions and investment strategies are based on verifiable evidence.

 

The first stage involves antigen selection and biological feasibility assessment. At this stage, Env-SU and other potential antigen candidates should be evaluated based on their immunological relevance, epitope conservation, and potential to induce immune responses associated with protection.

 

The second stage involves formulation development and quality characterization. Candidates based on PLGA, chitosan, or lipid nanoparticles (LNPs) should be compared in terms of their physicochemical properties, antigen integrity, delivery efficiency, and stability. Platform selection should be guided by experimental findings rather than the assumption that one material is inherently superior to another.

 

The third stage involves the evaluation of immunogenicity and preclinical safety using appropriate experimental systems. Assessments may include antibody responses, neutralizing activity where validated methods are available, cellular immune response profiles, and relevant safety indicators.

 

The fourth stage involves evaluation in Bali cattle through research designs that comply with ethical, biosafety, and regulatory requirements. These studies should be designed to compare vaccine candidates against appropriate controls and, where relevant, currently used comparator vaccines. Sample sizes, predefined success criteria, and statistical analysis plans should be established before the studies commence.

 

The fifth stage involves production assessment and implementation feasibility evaluation. Key aspects to be analyzed include batch-to-batch consistency, cost per dose, stability during distribution, user acceptance, and the need to strengthen disease surveillance and control systems.

 

The overall success of the development program should not be determined solely by the magnitude of antibody responses. Vaccine candidates must demonstrate an acceptable safety profile and meaningful protective benefits against the disease, supported by consistent manufacturing quality.

 

4. CONCLUSION

 

Nanotechnology offers strategic opportunities for the development of Jembrana disease virus (JDV) vaccines as an alternative to, or an improvement upon, existing tissue-based inactivated vaccines. Lipid nanoparticle (LNP) platforms have the potential to facilitate nucleic acid delivery and intracellular antigen expression, whereas poly(lactic-co-glycolic acid) (PLGA) and chitosan nanoparticles can be investigated for antigen protection and modulation of delivery characteristics.

 

Env-SU represents a relevant antigen candidate for inducing antibody responses against viral envelope proteins, while Tat may be investigated as a potential antigen source for eliciting cellular immune responses, with due consideration given to its safety and biological relevance. The combination of antigens and nanoparticle-based delivery systems may support the development of both humoral and cellular immune responses. However, the magnitude and protective benefits of these responses remain to be specifically demonstrated for JDV.

 

The major challenges in vaccine development include standardization of physicochemical properties, storage stability, production costs, biological safety, and demonstration of efficacy in Bali cattle. Therefore, research should be conducted through a phased approach, beginning with antigen selection and formulation characterization, followed by immunogenicity evaluation and subsequent safety and protective efficacy studies in the target animal species.

 

Through an evidence-based approach, the development of nanotechnology-based JDV vaccines has the potential to strengthen Indonesia's self-reliance in veterinary vaccine production, support Jembrana disease control, and contribute to the conservation and sustainability of Bali cattle populations as a valuable national livestock genetic resource.

 

5. REFERENCES

 

Desport, M., & Lewis, J. (2010). Jembrana disease virus: Host responses, viral dynamics and disease control. Current HIV Research, 8(1), 53–65. https://doi.org/10.2174/157016210790416370

 

Ditcham, W. G. F., Lewis, J. R., Dobson, R. J., Hartaningsih, N., Wilcox, G. E., & Desport, M. (2009). Vaccination reduces the viral load and the risk of transmission of Jembrana disease virus in Bali cattle. Virology, 386(2), 317–324. https://doi.org/10.1016/j.virol.2009.02.008

 

Hartaningsih, N., Dharma, D. M., Soeharsono, S., & Wilcox, G. E. (2001). The induction of a protective immunity against Jembrana disease in cattle by vaccination with inactivated tissue-derived virus antigens. Veterinary Immunology and Immunopathology, 78(2), 163–176. https://doi.org/10.1016/S0165-2427(00)00265-8

 

Schoenmaker, L., Witzigmann, D., Kulkarni, J. A., Verbeke, R., Kersten, G., Jiskoot, W., & Crommelin, D. J. A. (2021). mRNA-lipid nanoparticle COVID-19 vaccines: Structure and stability. International Journal of Pharmaceutics, 601, 120586. https://doi.org/10.1016/j.ijpharm.2021.120586

 

#JembranaVaccine

#Nanotechnology

#BaliCattle

#JDV

#AnimalHealth 

No comments: